Steven Cohen Mirum Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$23.51 - $30.09 $1.03 Million - $1.31 Million	43,600 Added 7.82%	601,038 $15.5 Million
Q1 2023 May 15, 2023	BUY	$19.19 - $24.1 $4.18 Million - $5.25 Million	217,928 Added 64.19%	557,438 $13.4 Million
Q4 2022 Feb 14, 2023	BUY	$17.59 - $23.83 $5.97 Million - $8.09 Million	339,510 New	339,510 $6.62 Million
Q2 2022 Aug 15, 2022	SELL	$18.42 - $27.5 $2.83 Million - $4.22 Million	-153,389 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$15.5 - $23.93 $2.5 Million - $3.86 Million	-161,454 Reduced 51.28%	153,389 $3.38 Million
Q4 2021 Feb 14, 2022	BUY	$13.05 - $19.35 $2.22 Million - $3.3 Million	170,443 Added 118.04%	314,843 $5.02 Million
Q3 2021 Nov 15, 2021	BUY	$13.95 - $20.18 $1.75 Million - $2.53 Million	125,600 Added 668.09%	144,400 $2.88 Million
Q2 2021 Aug 16, 2021	BUY	$15.84 - $20.6 $218,592 - $284,280	13,800 Added 276.0%	18,800 $325,000
Q1 2021 May 17, 2021	BUY	$16.29 - $21.92 $81,450 - $109,600	5,000 New	5,000 $99,000
Q3 2020 Nov 16, 2020	SELL	$18.4 - $26.59 $1.79 Million - $2.59 Million	-97,415 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$11.51 - $20.97 $1.12 Million - $2.04 Million	97,415 New	97,415 $1.9 Million

211

53.8M

2.6K

99.7K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.95B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.